Featured Research

from universities, journals, and other organizations

New Function For The Protein Bcl-xL: It Prevents Bone Breakdown

Date:
December 31, 2009
Source:
Journal of Clinical Investigation
Summary:
In blood cells, the protein Bcl-xL has a well-characterized role in preventing cell death by a process known as apoptosis. New research has now identified its functions in osteoclasts, cells that slowly breakdown bone (a process known as resorption). Surprisingly, not only does Bcl-xL prevent osteoclast apoptosis in mice, it also negatively regulates the bone-resorbing activity of osteoclasts.

In blood cells, the protein Bcl-xL has a well-characterized role in preventing cell death by a process known as apoptosis. However, its function(s) in osteoclasts, cells that slowly breakdown bone (a process known as resorption), has not been determined.

In addressing this issue, Sakae Tanaka and colleagues, at The University of Tokyo, Japan, have discovered that not only does Bcl-xL prevent osteoclast apoptosis in mice, it also negatively regulates the bone-resorbing activity of osteoclasts. They report their findings in the Journal of Clinical Investigation.

To determine the function of Bcl-xL in osteoclasts, the researchers generated mice lacking Bcl-xL only in osteoclasts. As in blood cells, Bcl-xL was shown to promote the survival of osteoclasts. Unexpectedly, however, the mutant mice exhibited marked osteopenia at one year of age. Further analysis indicated that the reduced bone mass was caused by increased osteoclast-mediated bone resorption and identified a potential underlying mechanism. Specifically, Bcl-xL was found to decrease the production of extracellular matrix proteins, which bind cell surface integrin molecules, leading to the activation of c-Src signaling pathways that are already known to promote osteoclast-mediated bone resorption.

Thus, in the absence of Bcl-xL, increased production of extracellular matrix proteins leads to increased osteoclast-mediated bone resorption.



Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Iwasawa et al. The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI39819

Cite This Page:

Journal of Clinical Investigation. "New Function For The Protein Bcl-xL: It Prevents Bone Breakdown." ScienceDaily. ScienceDaily, 31 December 2009. <www.sciencedaily.com/releases/2009/09/090914172339.htm>.
Journal of Clinical Investigation. (2009, December 31). New Function For The Protein Bcl-xL: It Prevents Bone Breakdown. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/09/090914172339.htm
Journal of Clinical Investigation. "New Function For The Protein Bcl-xL: It Prevents Bone Breakdown." ScienceDaily. www.sciencedaily.com/releases/2009/09/090914172339.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins